Literature DB >> 19944964

Glioblastoma-derived mechanisms of systemic immunosuppression.

Allen Waziri1.   

Abstract

Abnormalities of cellular immunity are commonly seen in patients with glioblastoma (GBM), and the subsequent relative immunosuppression likely contributes to poor tumor-specific responses in affected individuals. Endogenous immune regulation is likely to limit the efficacy of a wide array of immunotherapeutic strategies, therefore mandating consideration in the continued development of novel treatments for GBM. Various tumor-associated factors have been implicated as potential generators of the immunosuppressive effect. This article outlines relevant experimentation exploring the nature of immune defects in patients with GBM, including a critical discussion of tumor-secreted factors, cell-surface proteins, and more recently described populations of immunoregulatory leukocytes that have potential roles in the subversion of cellular immunity.

Entities:  

Mesh:

Year:  2010        PMID: 19944964     DOI: 10.1016/j.nec.2009.08.005

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  51 in total

1.  Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.

Authors:  Baisakhi Raychaudhuri; Patricia Rayman; Joanna Ireland; Jennifer Ko; Brian Rini; Ernest C Borden; Jorge Garcia; Michael A Vogelbaum; James Finke
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

2.  Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.

Authors:  Alexia Ghazi; Aidin Ashoori; Patrick J Hanley; Vita S Brawley; Donald R Shaffer; Yvonne Kew; Suzanne Z Powell; Robert Grossman; Zakaria Grada; Michael E Scheurer; Meenakshi Hegde; Ann M Leen; Catherine M Bollard; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk; Nabil Ahmed
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

Review 3.  Combining immunotherapy with radiation for the treatment of glioblastoma.

Authors:  Kevin K H Chow; Wendy Hara; Michael Lim; Gordon Li
Journal:  J Neurooncol       Date:  2015-04-17       Impact factor: 4.130

4.  Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients.

Authors:  Afsar Rahbar; Madeleine Cederarv; Nina Wolmer-Solberg; Charlotte Tammik; Giuseppe Stragliotto; Inti Peredo; Olesja Fornara; Xinling Xu; Mensur Dzabic; Chato Taher; Petra Skarman; Cecilia Söderberg-Nauclér
Journal:  Oncoimmunology       Date:  2015-08-24       Impact factor: 8.110

5.  Immunotherapy for glioblastoma: are we finally getting closer?

Authors:  Michael Lim
Journal:  Neuro Oncol       Date:  2015-05-10       Impact factor: 12.300

Review 6.  Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.

Authors:  David A Reardon; Mark R Gilbert; Wolfgang Wick; Linda Liau
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

7.  Scutellaria extract and wogonin inhibit tumor-mediated induction of T(reg) cells via inhibition of TGF-β1 activity.

Authors:  Sagar Dandawate; Linford Williams; Nirmal Joshee; Agnes M Rimando; Sandeep Mittal; Archana Thakur; Lawrence G Lum; Prahlad Parajuli
Journal:  Cancer Immunol Immunother       Date:  2011-11-06       Impact factor: 6.968

8.  Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells.

Authors:  Gregory J Baker; Peter Chockley; Daniel Zamler; Maria G Castro; Pedro R Lowenstein
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

9.  A comparison of DNA methylation specific droplet digital PCR (ddPCR) and real time qPCR with flow cytometry in characterizing human T cells in peripheral blood.

Authors:  John K Wiencke; Paige M Bracci; George Hsuang; Shichun Zheng; Helen Hansen; Margaret R Wrensch; Terri Rice; Melissa Eliot; Karl T Kelsey
Journal:  Epigenetics       Date:  2014-10       Impact factor: 4.528

10.  Glioma-derived extracellular vesicles selectively suppress immune responses.

Authors:  Justin E Hellwinkel; Jasmina S Redzic; Tessa A Harland; Dicle Gunaydin; Thomas J Anchordoquy; Michael W Graner
Journal:  Neuro Oncol       Date:  2015-09-18       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.